Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer and presents a 5-year survival rate of less than 10%. Novel therapies focusing on targeting the tumor microenvironment and dysregulated molecular signaling pathways are emerging as potential options for intervention.